{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T13:53:45Z","timestamp":1758635625391,"version":"3.44.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research in Veterinary Science"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.rvsc.2015.02.003","type":"journal-article","created":{"date-parts":[[2015,2,11]],"date-time":"2015-02-11T02:30:30Z","timestamp":1423621830000},"page":"137-144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Survivin suppressor (YM155) enhances chemotherapeutic efficacy against canine histiocytic sarcoma in murine transplantation models"],"prefix":"10.1016","volume":"99","author":[{"given":"Hiroki","family":"Yamazaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0551-8151","authenticated-orcid":false,"given":"Satoshi","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Hosoya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rvsc.2015.02.003_bib0010","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11060-008-9697-z","article-title":"What is the translational efficacy of chemotherapeutic drug research in neuro-oncology? A systematic review and meta-analysis of the efficacy of BCNU and CCNU in animal models of glioma","volume":"91","author":"Amarasingh","year":"2009","journal-title":"Journal of Neuro-Oncology"},{"key":"10.1016\/j.rvsc.2015.02.003_bib0015","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4137\/DTI.S12519","article-title":"P-glycoprotein inhibition for optimal drug delivery","volume":"7","author":"Amin","year":"2013","journal-title":"Drug Target Insights"},{"key":"10.1016\/j.rvsc.2015.02.003_bib0020","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1746-1596-7-52","article-title":"Survivin regulates the expression of VEGF-C in lymphatic metastasis of breast cancer","volume":"7","author":"Cai","year":"2012","journal-title":"Diagnostic Pathology"},{"key":"10.1016\/j.rvsc.2015.02.003_bib0025","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.yexcr.2004.12.014","article-title":"Survivin enhances telomerase activity via up-regulation of specificity protein 1- and c-Myc-mediated human telomerase reverse transcriptase gene transcription","volume":"305","author":"Endoh","year":"2005","journal-title":"Experimental Cell Research"},{"key":"10.1016\/j.rvsc.2015.02.003_bib0030","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.1200\/JCO.2008.21.1862","article-title":"Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer","volume":"27","author":"Giaccone","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.rvsc.2015.02.003_bib0035","doi-asserted-by":"crossref","first-page":"e55710","DOI":"10.1371\/journal.pone.0055710","article-title":"The detergent-soluble cytoplasmic pool of survivin suppresses anoikis and its expression is associated with metastatic disease of human colon cancer","volume":"8","author":"Hori","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.rvsc.2015.02.003_bib0040","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1124\/dmd.111.040733","article-title":"Utility of P-glycoprotein and organic cation transporter 1 double-transfected LLC-PK1 cells for studying the interaction of YM155 monobromide, novel small-molecule survivin suppressant, with P-glycoprotein","volume":"39","author":"Iwai","year":"2011","journal-title":"Drug Metabolism and Disposition: The Biological Fate of Chemicals"},{"key":"10.1016\/j.rvsc.2015.02.003_bib0045","doi-asserted-by":"crossref","first-page":"6496","DOI":"10.1158\/1078-0432.CCR-08-0468","article-title":"Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines","volume":"14","author":"Iwasa","year":"2008","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.rvsc.2015.02.003_bib0050","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/med.21264","article-title":"Survivin signaling in clinical oncology: a multifaceted dragon","volume":"33","author":"Kanwar","year":"2013","journal-title":"Medicinal Research Reviews"},{"key":"10.1016\/j.rvsc.2015.02.003_bib0055","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2460\/javma.239.1.90","article-title":"Evaluation and comparison of outcomes in dogs with periarticular and nonperiarticular histiocytic sarcoma","volume":"239","author":"Klahn","year":"2011","journal-title":"Journal of the American Veterinary Medical Association"},{"key":"10.1016\/j.rvsc.2015.02.003_bib0060","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1248\/bpb.30.2279","article-title":"The effect of survivin on multidrug resistance mediated by P-glycoprotein in MCF-7 and its adriamycin resistant cells","volume":"30","author":"Liu","year":"2007","journal-title":"Biological & Pharmaceutical Bulletin"},{"key":"10.1016\/j.rvsc.2015.02.003_bib0065","first-page":"1469","article-title":"Survivin transcription is associated with P-glycoprotein\/MDR1 overexpression in the multidrug resistance of MCF-7 breast cancer cells","volume":"23","author":"Liu","year":"2010","journal-title":"Oncology Reports"},{"key":"10.1016\/j.rvsc.2015.02.003_bib0070","doi-asserted-by":"crossref","first-page":"7927","DOI":"10.1158\/0008-5472.CAN-10-0194","article-title":"Survivin enhances motility of melanoma cells by supporting Akt activation and \u03b15 integrin upregulation","volume":"70","author":"McKenzie","year":"2010","journal-title":"Cancer Research"},{"key":"10.1016\/j.rvsc.2015.02.003_bib0075","doi-asserted-by":"crossref","first-page":"8014","DOI":"10.1158\/0008-5472.CAN-07-1343","article-title":"YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts","volume":"67","author":"Nakahara","year":"2007","journal-title":"Cancer Research"},{"key":"10.1016\/j.rvsc.2015.02.003_bib0080","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/CAD.0b013e328344ac68","article-title":"YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model","volume":"22","author":"Nakahara","year":"2011","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.rvsc.2015.02.003_bib0085","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s00432-003-0516-9","article-title":"In vivo establishment and characterization of a paclitaxel-resistant human ovarian cancer cell line showing enhanced growth properties and drug-resistance only in vivo","volume":"130","author":"Okugawa","year":"2004","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"key":"10.1016\/j.rvsc.2015.02.003_bib0090","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1111\/j.1939-1676.2010.0588.x","article-title":"Phase II, open-label trial of single-agent CCNU in dogs with previously untreated histiocytic sarcoma","volume":"24","author":"Rassnick","year":"2010","journal-title":"Journal of Veterinary Internal Medicine"},{"key":"10.1016\/j.rvsc.2015.02.003_bib0095","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.2174\/092986712801661040","article-title":"Survivin as a prognostic\/predictive marker and molecular target in cancer therapy","volume":"19","author":"R\u00f6del","year":"2012","journal-title":"Current Medicinal Chemistry"},{"key":"10.1016\/j.rvsc.2015.02.003_bib0100","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/MAJ.0b013e318239c4ee","article-title":"Survivin knockdown enhances gastric cancer cell sensitivity to radiation and chemotherapy in vitro and in nude mice","volume":"344","author":"Shen","year":"2012","journal-title":"The American Journal of the Medical Sciences"},{"key":"10.1016\/j.rvsc.2015.02.003_bib0105","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1158\/0008-5472.CAN-11-2315","article-title":"Expression and function of survivin in canine osteosarcoma","volume":"72","author":"Shoeneman","year":"2012","journal-title":"Cancer Research"},{"key":"10.1016\/j.rvsc.2015.02.003_bib0110","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1734-1140(12)70900-3","article-title":"The multidrug transporter P-glycoprotein in pharmacoresistance to antiepileptic drugs","volume":"64","author":"St\u0119pie\u0144","year":"2012","journal-title":"Pharmacological Reports"},{"key":"10.1016\/j.rvsc.2015.02.003_bib0115","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/annonc\/mdr353","article-title":"A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer","volume":"23","author":"Tolcher","year":"2012","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.rvsc.2015.02.003_bib0120","first-page":"603","article-title":"Disruption of survivin in K562 cells elevates telomerase activity and protects cells against apoptosis induced by the Bcr-abl kinase inhibitor STI571","volume":"6","author":"Wang","year":"2008","journal-title":"Cancer Therapy"},{"key":"10.1016\/j.rvsc.2015.02.003_bib0125","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.1158\/1078-0432.CCR-10-3410","article-title":"Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models","volume":"17","author":"Yamanaka","year":"2011","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.rvsc.2015.02.003_bib0130","doi-asserted-by":"crossref","first-page":"e79810","DOI":"10.1371\/journal.pone.0079810","article-title":"Inhibition of survivin influences the biological activities of canine histiocytic sarcoma cell lines","volume":"8","author":"Yamazaki","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.rvsc.2015.02.003_bib0135","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/jvim.12244","article-title":"Comparative analysis of mRNA expression of surface antigens between histiocytic and non-histiocytic sarcoma in dogs","volume":"28","author":"Yamazaki","year":"2014","journal-title":"Journal of Veterinary Internal Medicine"}],"container-title":["Research in Veterinary Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0034528815000454?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0034528815000454?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T04:01:46Z","timestamp":1758513706000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0034528815000454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":26,"alternative-id":["S0034528815000454"],"URL":"https:\/\/doi.org\/10.1016\/j.rvsc.2015.02.003","relation":{},"ISSN":["0034-5288"],"issn-type":[{"type":"print","value":"0034-5288"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survivin suppressor (YM155) enhances chemotherapeutic efficacy against canine histiocytic sarcoma in murine transplantation models","name":"articletitle","label":"Article Title"},{"value":"Research in Veterinary Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rvsc.2015.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}